Tibet Rhodiola Pharmaceutical Holding Co
SSE:600211
P/B
Price to Book Value
Price to Book Value (P/B) ratio is a valuation multiple that measures the market's valuation of a company relative to its book value. The P/B ratio is only considered useful in practice when applied to capital-intensive businesses.
Market Cap | P/B | ||||
---|---|---|---|---|---|
CN |
Tibet Rhodiola Pharmaceutical Holding Co
SSE:600211
|
12.2B CNY | 3.6 | ||
US |
Mckesson Corp
NYSE:MCK
|
71.9B USD | -36.4 | ||
US |
Cencora Inc
NYSE:COR
|
44.5B USD | 41.1 | ||
US |
Amerisourcebergen Corp
NYSE:ABC
|
35.4B USD | 51.5 | ||
US |
Cardinal Health Inc
NYSE:CAH
|
23.9B USD | -7.3 | ||
US |
Henry Schein Inc
NASDAQ:HSIC
|
9.5B USD | 2.6 | ||
CN |
Sinopharm Group Co Ltd
HKEX:1099
|
70.4B HKD | 0.9 | ||
KR |
C
|
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
12.2T KRW | 6 | |
IT |
Amplifon SpA
MIL:AMP
|
7.7B EUR | 7 | ||
CN |
Huadong Medicine Co Ltd
SZSE:000963
|
58.8B CNY | 2.8 | ||
CN |
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
53B CNY | 0.8 |
P/B Forward Multiples
Forward P/B multiple is a version of the P/B ratio that uses forecasted equity for the P/B calculation. 1-Year, 2-Years, and 3-Years forwards use equity forecasts for 1, 2, and 3 years ahead, respectively.